virus
known
genom
economi
prolif
abil
mutat
relat
former
instead
encod
larg
number
factor
virus
reli
number
host
factor
mediat
replic
properti
limit
number
viral
molecul
therapeut
target
particularli
small
molecul
therapi
furthermor
mutat
rate
high
error
per
nucleotid
per
genom
replic
rapidli
endow
virus
impress
sequenc
divers
allow
evad
host
immun
respons
sampl
mutat
path
may
yield
strain
resist
antivir
therapeut
result
increas
incid
resist
limit
number
antivir
drug
novel
therapi
must
one
readili
design
test
rna
interfer
rnai
recent
discov
evolutionarili
conserv
mechan
regul
gene
express
potenti
har
therapeut
altern
antivir
small
molecul
drug
process
cell
prime
identifi
degrad
rna
sequencespecif
manner
first
observ
petunia
shortli
thereaft
similar
phenomenon
found
natur
antivir
activ
plant
pathway
respons
activ
identifi
c
elegan
rnai
natur
antivir
activ
rnai
demonstr
c
elegan
melanogast
aegypti
importantli
conserv
pathway
vertebr
rnai
particularli
attract
antivir
therapi
strategi
review
focu
therapeut
applic
antivir
rnai
discuss
design
consider
includ
mode
express
deliveri
strategi
also
consid
shortcom
use
rnai
antivir
therapi
challeng
may
address
therapi
design
translat
clinic
rnai
pathway
highli
conserv
cellular
mechan
regul
gene
express
invertebr
anim
fig
long
doublestrand
rna
dsrna
process
nt
short
interf
rna
sirna
duplex
cellular
rnaseiii
enzym
call
dicer
one
strand
duplex
load
argonaut
guid
strand
creat
activ
rnainduc
silenc
complex
risc
choic
strand
made
base
thermodynam
properti
sirna
duplex
guid
strand
use
direct
risc
complementari
rna
perfectli
complementari
rna
slice
rnase
hlike
activ
argonaut
major
compon
risc
vertebr
fig
presenc
long
dsrna
precursor
induc
nonspecif
immun
respons
addit
rnai
rnai
specif
trigger
directli
introduc
sirna
duplex
cell
express
smaller
rna
short
hairpin
rna
shrna
process
dicer
sirna
duplex
pathway
mani
similar
rnai
endogen
express
microrna
mirna
also
serv
regul
gene
express
plant
anim
mirna
gener
express
longer
hairpin
rna
call
primari
mirna
primirna
contain
sever
mismatch
stemloop
primirna
process
cellular
complex
drosha
anim
gener
shrnalik
molecul
call
precursor
mirna
premirna
premirna
process
dicer
load
risc
manner
similar
sirna
defin
properti
mirna
typic
mismatch
mirna
guid
target
mrna
result
mirna
gener
regul
gene
express
repress
translat
instead
direct
cleavag
target
though
rna
degrad
occur
via
altern
mechan
decap
deadenyl
sequencespecif
natur
rnai
provid
sever
advantag
develop
antivir
treatment
first
sinc
rnai
act
nucleotid
level
inform
necessari
begin
design
rnai
therapeut
target
sequenc
consider
acceler
rate
potenti
therapi
enter
drug
develop
pipelin
second
antivir
small
molecul
gener
act
specif
biochem
inhibit
viral
protein
function
accompani
nonspecif
interact
host
factor
result
detriment
side
effect
neg
impact
longterm
patient
health
complianc
rnai
certainli
offtarget
effect
interact
host
mrna
close
sequenc
viral
target
howev
unlik
small
moleculeprotein
interact
nucleotid
sequenc
watsoncrick
base
pair
provid
straightforward
mean
differenti
host
whose
genom
sequenc
cours
known
pathogen
principl
specif
inhibit
virus
could
potenti
achiev
reduc
incid
side
effect
ideal
choos
rnai
target
essenti
viral
replic
could
viral
host
factor
target
viral
factor
import
consid
point
viral
life
cycl
target
access
rnaimedi
degrad
exampl
addit
use
rnai
target
newli
transcrib
viral
mrna
virus
posit
sens
rna
genom
hepat
c
viru
hcv
human
immunodefici
viru
hiv
may
suscept
degrad
even
earlier
initi
infect
entri
cell
addit
altern
splice
viral
genom
may
mean
viral
target
present
splice
variant
present
earli
late
gene
express
furthermor
recent
comput
model
suggest
target
region
transcrib
earli
includ
mani
transcript
help
maxim
impact
therapeut
rna
degrad
viral
rna
earli
often
although
viral
factor
repres
clear
target
like
essenti
replic
readili
distinguish
host
factor
rapid
evolut
virus
mean
target
mutat
select
resist
rnai
discuss
viral
resist
rnai
detail
two
option
avoid
resist
target
highli
conserv
viral
factor
less
mutabl
host
factor
primari
advantag
host
target
sequenc
constant
rel
rapidli
evolv
viral
genom
though
one
clear
complic
may
requir
host
function
health
host
factor
may
essenti
case
inhibit
express
hiv
infect
case
host
factor
essenti
mainten
cell
health
serv
effect
target
level
knockdown
requir
inhibit
viral
replic
affect
endogen
function
factor
case
vitro
knock
transcript
elong
factor
suppress
hiv
infect
nonetheless
inhibit
host
factor
care
screen
undesir
side
effect
conduct
cell
cultur
anim
model
prior
implement
human
final
mention
model
effort
suggest
target
earli
point
viral
life
cycl
essenti
therapeut
efficaci
host
factor
use
viral
entri
genom
replic
repres
addit
option
act
earli
viral
life
cycl
matur
high
throughput
screen
method
number
largescal
rnai
screen
recent
conduct
identifi
host
factor
involv
viral
infect
hiv
influenza
hcv
west
nile
viru
wnv
hit
emerg
screen
could
feed
target
valid
effort
addit
expand
type
virus
host
cell
line
use
screen
increas
number
potenti
host
target
antivir
rnai
therapi
improv
confid
screen
common
hit
emerg
multipl
screen
provid
insight
whether
particular
factor
essenti
healthi
function
host
cell
upon
choos
host
viral
target
knockdown
specif
sequenc
must
identifi
secondari
structur
target
rna
well
thermodynam
stabil
sirna
duplex
guidetarget
duplex
greatli
affect
efficaci
rnai
gener
rnai
target
unstructur
possibl
particularli
termini
target
region
order
improv
target
access
risc
addit
thermodynam
properti
associ
activ
sirna
includ
low
gc
content
asymmetr
instabl
sirna
duplex
mean
effect
duplex
lower
intern
stabil
end
compar
end
antisens
strand
asymmetr
interact
guid
strand
target
rna
within
risc
end
guid
stand
respons
surpass
thermodynam
threshold
stabil
target
rna
effect
degrad
optim
target
also
minim
offtarget
effect
ideal
small
molecul
pharmaceut
minim
interact
target
beyond
therapeut
desir
check
sequenc
homolog
target
host
genom
minim
effect
furthermor
leverag
degre
specif
posit
natur
mismatch
guid
strand
target
rna
affect
sirna
activ
specif
one
potenti
distinguish
target
offtarget
region
exhibit
high
degre
sequenc
similar
comput
effort
also
aid
improv
target
predict
number
generalus
websit
sirna
design
develop
industri
academia
consid
thermodynam
requir
sirna
potenti
offtarget
effect
though
resourc
design
address
need
target
highli
conserv
region
virus
mitig
viral
escap
two
design
servic
develop
fill
nich
antivir
rnai
therapi
design
siviru
webbas
applic
streamlin
antivir
rnai
design
implement
sever
algorithm
creat
function
sirna
target
highli
conserv
region
viru
consid
potenti
offtarget
effect
current
softwar
sequenc
data
identifi
highli
conserv
region
hiv
sar
hcv
influenza
second
even
third
gener
sequenc
technolog
lower
cost
largescal
sequenc
known
genet
divers
mani
virus
capabl
siviru
presum
grow
anoth
freeli
avail
piec
softwar
specif
viral
sirna
design
capsid
search
activ
sirna
minim
potenti
offtarget
effect
highli
conserv
region
viral
genom
guidanc
userprovid
sampl
viru
sequenc
flexibl
mean
capsid
wide
applic
differ
virus
howev
limit
userprovid
sequenc
data
could
bia
result
note
impact
comput
model
antivir
sirna
design
limit
target
select
addit
insight
class
comput
work
provid
addit
sirna
sequenc
select
discuss
librari
approach
also
use
identifi
effect
target
necessarili
conform
gener
thermodynam
structur
rule
outlin
probe
everi
possibl
target
individu
everdecreas
cost
oligonucleotid
synthesi
multiplex
technolog
bring
potenti
complet
sirna
coverag
shorter
viral
genom
reach
altern
method
gener
librari
use
enzymat
approach
develop
near
complet
sirna
coverag
achiev
process
genom
dna
cdna
shrna
use
combin
special
restrict
endonucleas
loop
adaptor
method
rnai
induct
mechan
rnai
pathway
trigger
therapeut
purpos
also
consider
impact
efficaci
depend
type
infect
treat
mention
earlier
rnai
trigger
use
varieti
effector
agent
includ
synthet
sirna
geneencod
shrna
choic
among
option
import
implic
therapeut
applic
exampl
acut
exist
infect
treat
administr
synthet
sirna
though
delay
initi
treatment
follow
initi
infect
limit
therapeut
benefit
hand
treatment
chronic
infect
prophylact
use
rnai
prevent
incept
viral
infect
may
requir
sustain
induct
repeat
deliveri
synthet
sirna
possibl
geneencod
effector
agent
shrna
though
riskbenefit
ratio
latter
must
consid
sustain
induct
could
accomplish
invertebr
genet
engin
invert
repeat
rna
ir
rna
sirna
express
cassett
host
cell
genom
vertebr
sustain
induct
like
accomplish
geneencod
sirna
express
genet
engin
cell
period
administr
synthet
sirna
depend
natur
host
invertebr
versu
vertebr
natur
infect
acut
chronic
treatment
object
prevent
preexist
necess
difficulti
maintain
sustain
express
singl
repeat
administr
one
method
rnai
induct
may
desir
anoth
mode
induct
chosen
deliveri
strategi
must
also
determin
synthet
sirna
simpli
administ
nake
rna
though
poor
rna
stabil
limit
efficaci
approach
sirna
stabil
improv
chemic
modif
deliveri
enhanc
encapsul
sirna
synthet
vehicl
cation
liposom
though
direct
sirna
specif
cell
interest
remain
challeng
address
problem
sirna
conjug
target
antibodi
peptid
aptam
target
particular
cell
type
infect
cell
geneencod
rnai
effector
nake
plasmid
dna
administr
option
though
deliveri
effici
typic
limit
higher
effici
express
cassett
deliv
via
viral
vector
use
viral
vector
improv
one
abil
target
cell
interest
exampl
lentivir
vector
use
system
deliveri
divid
nondivid
cell
retrovir
vector
limit
infect
divid
cell
popul
stem
cell
system
deliveri
gener
result
target
liver
spleen
recent
discov
variant
vector
adenoassoci
viru
aav
also
transduc
muscl
even
central
nervou
system
upon
system
inject
altern
direct
inject
desir
tissu
could
aid
target
particular
cell
therapeut
interest
futur
system
direct
administr
could
also
aid
transit
ex
vivo
deliveri
approach
recent
use
gener
hematopoiet
stem
cell
protect
hiv
replic
readili
administ
vivo
deliveri
method
despit
deliveri
advantag
lenti
retrovir
vector
pose
risk
genotox
due
vector
integr
risk
decreas
use
viral
vector
aav
provid
stabl
gene
express
episom
viral
genom
without
explicit
need
integr
engin
retrovir
vector
exhibit
zinc
fingermedi
sitespecif
integr
adenovir
vector
transient
gene
express
cellular
express
sirna
also
afford
degre
control
exampl
tissuespecif
viral
infectionspecif
promot
shown
drive
sirna
product
therapeut
relev
cell
thu
reduc
risk
offtarget
effect
deliveri
improv
function
deliveri
vehicl
via
chemic
protein
conjug
vector
pseudotyp
engin
viral
capsid
target
deliveri
reduc
total
amount
sirna
express
cassett
requir
treatment
thu
reduc
potenti
risk
offtarget
effect
well
potenti
cost
therapi
comput
model
antivir
rnai
also
provid
signific
insight
therapi
design
two
studi
consid
longterm
antivir
rnai
therapi
identifi
critic
constraint
therapi
paramet
could
significantli
affect
therapi
outcom
first
investig
stochast
model
develop
understand
specif
therapi
paramet
impact
efficaci
viral
escap
antihiv
sirna
model
first
kind
simul
molecular
level
detail
viru
replic
respons
therapeut
rnai
depend
rnai
inhibit
effici
model
suggest
two
four
target
requir
maintain
longterm
inhibit
without
escap
also
predict
threshold
exist
size
reservoir
unprotect
cell
cell
harbor
sirna
toler
therapi
success
predict
subsequ
valid
vitro
recent
studi
simul
hiv
infect
lymphoid
tissu
larger
vivolik
model
evalu
efficaci
biolog
relev
engraft
effici
rang
find
larger
reservoir
unprotect
cell
may
detriment
therapi
efficaci
provid
rnai
therapi
abl
degrad
incom
viral
genom
prior
integr
latter
capabl
debat
howev
rnai
therapi
may
need
combin
anoth
therapi
capabl
target
incom
viral
genom
full
efficaci
test
predict
expans
model
simul
virus
altern
mode
rnai
induct
continu
improv
predict
power
applic
eas
rnai
design
increas
number
therapi
develop
pipelin
provid
larg
number
potenti
sirna
target
within
singl
viral
gene
readili
test
cell
cultur
preclin
anim
model
howev
therapi
face
challeng
convent
antivir
therapi
encount
clinic
viral
escap
singl
nucleotid
substitut
rnai
target
site
within
viral
genom
result
complet
loss
interfer
depend
locat
natur
result
mismatch
addit
nucleotid
substitut
target
fig
viral
resist
emerg
delet
target
indirect
structur
rearrang
target
region
even
mutat
promoterenhanc
element
far
target
site
increas
viral
gene
transcript
therebi
overwhelm
rnai
machineri
elev
number
viral
transcript
viral
escap
rnai
suppress
document
hiv
hcv
polioviru
addit
rna
dna
virus
pose
addit
problem
preexist
quasispeci
divers
rnairesist
clone
may
alreadi
present
within
host
prior
therapeut
rna
administr
number
strategi
suggest
circumv
prevent
emerg
resist
rnai
mention
virus
often
coopt
mani
host
factor
facilit
viral
replic
target
host
factor
involv
viral
replic
instead
viral
factor
like
reduc
risk
viral
escap
viru
mutat
host
factor
strategi
demonstr
inhibit
replic
hiv
human
lymphotrop
viru
htlv
influenza
hcv
effect
host
target
alway
avail
suffici
circumv
viral
escap
anoth
approach
target
highli
conserv
region
viral
genom
region
constrain
overlap
read
frame
import
function
codon
start
codon
primer
bind
site
structur
nucleic
acid
featur
ire
packag
signal
splice
site
export
signal
may
less
abl
toler
mutat
compromis
function
secondari
advantag
target
highli
conserv
region
rnai
target
may
effect
multipl
subtyp
serotyp
genotyp
demonstr
hiv
hbv
howev
mention
earlier
direct
mutat
viral
target
alway
necessari
viral
escap
target
highli
conserv
element
guarante
longterm
inhibit
without
escap
anoth
strategi
reduc
escap
target
multipl
factor
rnai
combinatori
rnai
approach
result
synergist
suppress
viral
replic
exampl
also
demonstr
delay
onset
escap
hiv
multitarget
approach
also
combin
previous
mention
two
strategi
target
highli
conserv
viral
factor
less
mutabl
host
factor
inhibit
hiv
hcv
replic
comput
estim
least
four
rnai
target
would
requir
success
circumv
viral
escap
yet
maintain
express
activ
multipl
sirna
trivial
problemat
exampl
shown
vivo
high
level
exogen
sirna
competit
interfer
endogen
activ
mirna
natur
function
rnai
pathway
addit
competit
among
variou
exogen
sirna
rnai
machineri
may
lower
overal
benefit
attain
use
multipl
sirna
bia
interfer
toward
singl
sirna
select
incorpor
risc
thu
elimin
advantag
gain
combinatori
approach
case
chronic
infect
prophylact
prevent
infect
sustain
longterm
express
desir
product
multipl
sirna
singl
vector
plasmid
difficult
engin
maintain
sever
strategi
achiev
pursu
advantag
shortcom
straightforward
includ
repeat
express
cassett
singl
backbon
done
seven
shrna
cassett
target
differ
hiv
gene
driven
rna
polymeras
iii
pol
iii
promot
strategi
eleg
eas
design
suffer
difficulti
implement
therapi
repeat
sequenc
elimin
recombin
transduct
host
cell
especi
mediat
retrovir
vector
effort
reduc
repeat
sequenc
altern
promot
sirna
product
use
place
tradit
use
pol
iii
promot
includ
pol
iii
tre
cmv
pol
ii
promot
option
reduc
level
repeat
sequenc
present
singl
construct
promot
may
requir
finetun
optim
express
variou
host
tissu
thu
complic
therapi
design
final
multipl
sirna
express
singl
promot
use
long
hairpin
rna
lhrna
polycistron
mirna
express
strategi
number
sirna
excis
process
singl
mrna
precursor
strategi
reduc
likelihood
cassett
delet
activ
sirna
reli
effici
process
actual
vari
specif
placement
within
extend
rna
product
addit
therapi
advantag
eas
speed
design
eleg
combin
may
involv
consider
engin
could
slow
develop
altern
deliveri
strategi
combinatori
therapi
recent
investig
silico
individu
compon
combin
either
equal
distribut
among
cell
popul
compartment
differ
cell
subpopul
depend
efficaci
therapi
rel
fit
resist
mutant
compartment
strategi
could
provid
therapeut
benefit
similar
equal
distribut
combin
therapi
yet
avoid
extra
engin
requir
sustain
combinatori
rnai
induct
potenti
circumv
risk
overwhelm
rnai
pathway
numer
therapeut
sirna
singl
cell
altern
strategi
combat
resist
shown
studi
evolut
resist
specif
sirna
due
specif
mutat
particular
base
posit
viru
combinatori
deliveri
multipl
sirna
whose
sequenc
correspond
parent
viru
like
escap
mutant
could
preemptiv
reduc
risk
viral
escap
howev
variant
sirna
effect
inhibit
replic
correspond
mutant
viru
like
due
chang
thermodynam
characterist
sirna
furthermor
unclear
whether
best
strategi
mutant
exist
start
treatment
correspond
sirna
could
thu
compet
effect
sirna
target
wildtyp
strain
combinatori
strategi
also
extend
encompass
antivir
therapi
combin
novel
rnabas
gene
therapi
includ
rnai
ribozym
rna
decoy
current
test
import
clinic
trial
hiv
analog
coxsackieviru
therapi
combin
rnai
antibodi
inhibit
viral
uptak
test
vitro
combin
rnai
convent
therapi
also
test
vitro
vivo
rnai
target
hcv
success
combin
tradit
interferon
therapi
inhibit
hcv
replic
synergist
vivo
combin
also
advantag
contend
exist
resist
anoth
exampl
rnai
combin
nucleosid
revers
transcript
inhibitor
nrti
inhibit
hiv
mixtur
contain
wild
type
nrtiresist
strain
may
particularli
fruit
line
applic
resist
mechan
first
line
antiretrovir
often
well
document
rnai
combin
nrti
also
shown
effect
suppress
viral
replic
wild
type
rnairesist
viru
use
low
nrti
concentr
alon
insuffici
inhibit
wild
type
replic
thu
rnai
serv
lower
dosag
need
convent
therapi
decreas
likelihood
side
effect
improv
likelihood
continu
patient
complianc
requir
avoid
develop
resist
exist
therapi
natur
role
rnai
antivir
mechan
mani
organ
consid
advantag
translat
rnai
gener
antivir
therapi
advantag
also
lead
complic
mani
virus
infect
organ
evolv
mechan
suppress
rnai
hijack
pathway
use
viral
suppressor
rnai
first
discov
plant
virus
sinc
identifi
virus
infect
invertebr
vertebr
anim
though
extent
rnai
play
natur
role
antivir
defens
mammal
extent
viral
protein
truli
suppress
innat
antivir
rnai
question
nonetheless
virus
certain
host
evolv
varieti
mechan
subvert
innat
antivir
rnai
possibl
sustain
rnai
treatment
host
may
forc
even
evolut
suppressor
subvert
innat
therapeut
rnai
final
exampl
may
challeng
use
rnai
therapi
ebola
hiv
la
cross
viru
particular
virus
document
rnai
suppressor
function
mammalian
host
mosquito
vector
rnai
conjunct
anoth
therapi
inhibit
suppressor
function
may
promis
strategi
final
hiv
hsv
notori
capac
form
latent
infect
shown
use
endogen
mirna
virusderiv
mirna
modul
viral
gene
express
latenc
epsteinbarr
viru
ebv
human
cytomegaloviru
hcmv
also
shown
gener
viral
mirna
thought
play
role
develop
mainten
latenc
ebv
hcmv
immun
evas
elucid
mechan
innat
rnai
suppress
immun
evas
latenc
help
guid
develop
new
therapi
strategi
abil
virus
inhibit
rnai
pathway
hijack
rnai
resourc
regul
viral
gene
express
could
limit
number
gene
could
reason
target
rnai
therapi
overwhelm
pathway
rnai
therapi
present
consider
therapeut
opportun
sever
rnai
therapi
reach
clinic
rel
short
time
class
therapeut
develop
date
four
antivir
rnai
therapi
enter
clinic
trial
tabl
ii
respiratori
syncyti
viru
rsv
hbv
hcv
hiv
trial
repres
major
advanc
antivir
rnai
therapi
field
also
provid
insight
may
acceler
futur
clinic
rnai
effort
first
initi
success
translat
therapi
clinic
may
come
synthet
sirna
therapeut
effector
least
acut
infect
may
pose
fewer
risk
compar
geneencod
counterpart
approach
success
use
protect
patient
rsv
infect
clinic
trial
hand
desir
treat
chronic
infect
hiv
sustain
rnai
genemodifi
cell
recent
util
digiusto
colleagu
practic
speak
advanc
drug
develop
process
synthet
sirna
compar
geneencod
shrna
may
result
faster
clinic
evalu
sirna
short
term
howev
sustain
express
necessari
longterm
solut
chronic
infect
hiv
taken
togeth
rnai
stand
make
consider
impact
treatment
acut
chronic
viral
infect
addit
sever
larg
pharmaceut
compani
exit
human
rnai
therapi
field
treat
nonhuman
host
livestock
may
repres
test
bed
provid
insight
aid
longerterm
human
therapeut
develop
rnai
nonhuman
host
like
also
face
fewer
regulatori
limit
therapi
may
commerci
faster
allevi
concern
viabil
recent
exampl
chicken
prophylact
treat
induc
rnai
target
marek
diseas
viru
mdv
shown
increas
resist
infect
strategi
could
potenti
use
combat
particularli
lethal
strain
influenza
usual
transmit
human
via
close
contact
poultri
similarli
rnai
prophylact
induc
pig
target
foot
mouth
diseas
viru
fmdv
also
infect
human
given
anatom
physiolog
similar
pig
human
great
deal
could
learn
efficaci
deliveri
longterm
viabil
conduct
smaller
studi
nonhuman
host
translat
result
human
also
number
therapeut
rnai
applic
invertebr
could
signific
impact
public
health
mosquito
serv
vector
number
tropic
virus
includ
dengu
viru
nyong
nyong
viru
onnv
wnv
yellow
fever
viru
yfv
prime
mosquito
onnv
dsrna
shown
decreas
spread
viru
insect
host
strategi
could
serv
gener
mechan
control
transmiss
addit
vectorborn
virus
recent
dengu
virusresist
transgen
mosquito
creat
use
invert
repeat
rna
express
cassett
specif
activ
mosquito
midgut
blood
meal
mosquito
demonstr
significantli
reduc
transmiss
dengu
viru
though
stabil
rnai
express
multipl
gener
decreas
research
popul
replac
strategi
could
make
eleg
strategi
viabl
sinc
mechan
rnai
first
elucid
c
elegan
use
treat
viral
infect
spread
like
epidem
abil
design
therapi
base
simpl
sequenc
inform
thermodynam
guidelin
potenti
acceler
therapeut
develop
furthermor
number
virusspecif
rnai
comput
design
tool
grow
target
predict
base
viral
constraint
sequenc
conserv
improv
deliveri
remain
challeng
rnai
therapi
applic
progress
target
transduct
progress
allevi
shortcom
furthermor
comput
effort
elucid
import
therapi
paramet
clinic
success
number
rnai
target
effici
transduct
help
defin
target
improv
final
rnai
target
human
virus
importantli
enter
clinic
treatment
livestock
vector
use
antivir
rnai
overlook
may
applic
easier
commerci
due
lower
regulatori
barrier
result
could
also
gener
translat
clinic
public
health
benefit
peopl
